文献速递外周动脉疾病

开放外周动脉旁路术后直接口服抗凝药与出血和血栓结局的关联

Bleeding and thrombotic outcomes associated with postoperative use of direct oral anticoagulants after open peripheral artery bypass procedures.
PubMed 文献 · J Vasc Surg · 2020-04-08

基于全州多中心质量改进登记,分析2012至2017年9682例开放外周旁路患者术后抗凝治疗与结局。与维生素K拮抗剂相比,直接口服抗凝药(DOAC)组住院更短、30天输血更少,且不劣化移植物通畅率、截肢率及抗凝并发症再入院。多数受访外科医生已采用DOAC替代VKA保护高危旁路。

要点

  • DOAC组住院中位6天,短于VKA组8天,无抗凝组5天最短。
  • DOAC与VKA在移植物通畅、截肢及抗凝并发症再入院方面无差异。

核心结论

  • 开放下肢旁路术后使用DOAC者较VKA者住院更短、30天输血更少,且未损害移植物通畅率、截肢率或抗凝并发症再入院。

研究设计与样本

  • 回顾性多中心质量改进登记研究,纳入2012年1月至2017年12月接受外周旁路手术的9682例患者。
  • 术后未抗凝7685例,VKA 1379例,DOAC 618例;并对参与登记的外科医生进行DOAC实践模式调查。

主要发现

  • 抗凝组较未抗凝组BMI更高,术前贫血、充血性心力衰竭和房颤更常见(均P<.001)。
  • DOAC组较VKA组慢性肾病更少(P=.002),房颤更多(P<.001)。
  • 住院中位天数:未抗凝组5天(IQR 3-9),DOAC组6天(IQR 3-11),VKA组8天(IQR 5-13),P<.001。
  • DOAC组与VKA组在抗凝并发症再入院、旁路血栓切除或溶栓、大截肢或1年移植物通畅率方面无差异。

临床怎么用

  • 对于开放外周旁路术后需抗凝的患者,DOAC可考虑作为VKA的替代选择,以缩短住院并降低30天输血风险。
  • 约70%受访外科医生报告有时或总是使用DOAC替代VKA保护高危旁路,提示需前瞻性试验验证DOAC的安全性与有效性。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Widespread adoption of direct oral anticoagulants (DOACs) for atrial fibrillation and venous thromboembolism treatment has resulted in peripheral bypass patients receiving therapeutic anticoagulation with DOACs postoperatively. This study was undertaken to evaluate patient outcomes after open peripheral bypass based on anticoagulation treatment. METHODS: Postoperative treatment and outcomes of patients undergoing peripheral bypass operations between January 2012 and December 2017 from a statewide multicenter quality improvement registry were examined. Surgeons participating in the registry were surveyed on practice patterns regarding DOACs in bypass patients. Multivariate logistic regression was performed for 30-day transfusion outcomes, and multiple linear regression was performed for length of stay. RESULTS: Among 9682 patients, 7685 patients received no anticoagulation, whereas 1379 received a vitamin K antagonist (VKA) and 618 received a DOAC postoperatively. Patients receiving anticoagulation compared with no anticoagulation had a higher body mass index and were more likely to have preoperative anemia, congestive heart failure, and atrial fibrillation (all P < .001). Compared with patients receiving VKAs, patients receiving DOACs were less likely to have chronic kidney disease (P = .002) and more likely to have atrial fibrillation (P < .001). The shortest length of stay was among patients receiving no anticoagulation (median, 5 days; interquartile range, 3-9 days; P < .001), followed by DOACs (median, 6 days; interquartile range 3-11 days; P < .001) and VKAs (median, 8 days; interquartile range, 5-13 days; P < .001). Compared with patients receiving VKAs postoperatively, there was no difference in readmission for anticoagulation complications, bypass thrombectomy or thrombolysis, major amputation, or graft patency at 1 year among patients receiving DOACs. On multivariate logistic regression, patients receiving a DOAC (odds ratio, 0.743; confidence interval, 0.59-0.94; P = .011) or no anticoagulation (odds ratio, 0.792; confidence interval, 0.69-0.91; P = .001) were less likely to require transfusion within 30 days than patients taking VKAs. Approximately 70% of the surveyed surgeons reported that they "sometimes" or "always" use DOACs instead of VKAs for protection of a high-risk bypass. CONCLUSIONS: Among patients undergoing lower extremity surgical bypass, those receiving a DOAC postoperatively had a shorter length of stay and were less likely to receive a transfusion in 30 days without compromising graft patency and readmission for anticoagulation complications, thrombectomy, or thrombolysis or affecting amputation rate compared with those receiving a VKA. A majority of surgeons within the quality collaborative have adopted the use of DOACs after peripheral bypass, suggesting the need for a prospective trial evaluating DOAC safety and efficacy in patients requiring anticoagulation for high-risk bypass grafts.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Obi AT, Thompson JR, Beaulieu RJ, et al. Bleeding and thrombotic outcomes associated with postoperative use of direct oral anticoagulants after open peripheral artery bypass procedures. J Vasc Surg. 2020. PMID: 32278573. doi:10.1016/j.jvs.2020.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。